Expected Response to the Additional Fifth Dose of COVID‑19 Vaccine

Rujittika Mungmunpuntipantip, Viroj Wiwanitkit

Abstract


Dear Editor, COVID‑19 is still a global emergency with no effective treatment.[1] Vaccination is the best option for managing the spread of this disease.[2] COVID‑19 vaccination is now universally acknowledged as an effective primary COVID‑19 preventive strategy. Traditionally, two vaccine doses are necessary for full vaccination. After complete vaccination, immunity levels may diminish, necessitating the use of self‑protective behavior. When there is a new developing variant and a potential decline in antibodies after completion of routine immunization, several experts recommend using an additional booster dose of the COVID‑19 vaccine.[3,4] In general, vaccine effectiveness against COVID‑19 infection wanes significantly 5‑8 months after completion of immunization, which is why COVID‑19 vaccine booster injections are required.

International Journal of Preventive Medicine 14(1):112, September 2023. | DOI: 10.4103/ijpvm.ijpvm_146_22

 

Corresponding Author: Dr. Rujittika Mungmunpuntipantip

E‑mail: rujittika@gmail.com

You can also search for this author in: PubMed  Google Scholar


Keywords


COVID‑19; Vaccine; Vaccination

Full Text:

PDF

References


Hsia W. Emerging new coronavirus infection in Wuhan, China:

Situation in early 2020. Case Study Case Rep 2020;10:8‑9.

Soleimanpour S, Yaghoubi A. COVID‑19 vaccine: Where

are we now and where should we go? Expert Rev Vaccines

;20:23‑44.

Shekhar R, Garg I, Pal S, Kottewar S, Sheikh AB. COVID‑19

vaccine booster: To boost or not to boost. Infect Dis Rep

;13:924‑9.

Krause PR, Fleming TR, Peto R, Longini IM, Figueroa JP,

Sterne JAC, et al. Considerations in boosting COVID‑19 vaccine

immune responses. Lancet 2021;398:1377‑80.

Mahase E. COVID‑19: Third vaccine dose boosts immune

response but may not be needed, say researchers. BMJ

;373:n1659.

Barda N, Dagan N, Cohen C, Hernán MA, Lipsitch M,

Kohane IS, et al. Effectiveness of a third dose of the BNT162b2

mRNA COVID‑19 vaccine for preventing severe outcomes in

Israel: An observational study. Lancet 2021;398:2093‑100.

Burki TK.Fourth dose of COVID‑19 vaccines in Israel. Lancet Respir Med 2022;10:e19.

Abedon AT, Teles MS, Alejo JL, Kim JD, Mitchell J,

Chiang TPY, et al. Improved antibody response after a fifth dose

of a SARS‑CoV‑2 vaccine in solid organ transplant recipients:

A case series. Transplantation 2022;106:e262‑3.

Sookaromdee P, Wiwanitkit V. New COVID‑19 vaccines, its

cost and shelf life: A cost effectiveness analysis. Arch Med Res

;52:453.

Yasri S, Wiwanitkit V. Expected response to the additional third

dose of COVID‑19 vaccine based on different complete standard

vaccination background. Int J Physiol Pathophysiol Pharmacol

;14:1‑3.

Fucci A, Giacobbe S, Guerriero I, Suzumoto Y, D’Andrea EL,

Scrima M, et al. The DiaCoVAb study in South Italy: Immune

response to Sars‑CoV‑2 vaccination in dialysis patients. Kidney

Blood Press Res 2022. doi: 10.1159/000524034.

Alejo JL, Mitchell J, Chiang TP, Abedon AT, Boyarsky BJ,

Avery RK, et al.Antibody response to a fourth dose of a

SARS‑CoV‑2 vaccine in solid organ transplant recipients: A case

series. Transplantation 2021;105:e280‑1.

Caillard S, Thaunat O, Benotmane I, Masset C, Blancho G.

Antibody response to a fourth messenger RNA COVID‑19

vaccine dose in kidney transplant recipients: A case series. Ann

Intern Med 2022;175:455‑6.

Kamar N, Abravanel F, Marion O, Romieu‑Mourez R, Couat C,

Del Bello A, et al. Assessment of 4 doses of SARS‑CoV‑2

messenger RNA‑based vaccine in recipients of a solid organ

transplant. JAMA Netw Open 2021;4:e2136030.

Regev‑Yochay G, Gonen T, Gilboa M, Mandelboim M,

Indenbaum V, Amit S, et al. Efficacy of a fourth dose of

Covid‑19 mRNA vaccine against omicron. N Engl J Med

;386:1377‑80.

Abbasi J. Fourth COVID‑19 vaccine dose increases low

antibodies. JAMA 2022;327:517.